The stock of Ceapro Inc. (CVE:CZO) is a huge mover today! The stock last traded at $1.32 per share. It is down 6.00% since October 31, 2016 and is uptrending. It has outperformed by 0.77% the S&P500.
The move comes after 8 months positive chart setup for the $92.42 million company. It was reported on Nov, 30 by Barchart.com. We have $1.39 PT which if reached, will make CVE:CZO worth $4.62M more.
More notable recent Ceapro Inc. (CVE:CZO) news were published by: Finance.Yahoo.com which released: “Ceapro Inc. Reports Third Quarter 2016 Financial and Operational Results” on November 23, 2016, also Seekingalpha.com with their article: “Ceapro: A Small, Profitable, Fast-Growing Biotechnology Company” published on November 04, 2016, Marketwired.com published: “Ceapro Inc. Announces the Grand Opening of New Bio-processing Extraction Facility” on September 28, 2016. More interesting news about Ceapro Inc. (CVE:CZO) were released by: Marketwired.com and their article: “Crystal Research Associates, LLC Issues Executive Informational Overview on …” published on November 14, 2016 as well as Marketwired.com‘s news article titled: “Ceapro Inc. Provides 2015 Business Highlights and 2016 Business Outlook” with publication date: April 18, 2016.
Ceapro Inc. is a Canada-based growth-stage biotechnology company. The company has a market cap of $92.42 million. The Company’s primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human and animal health industries using technology, natural and renewable resources. It has a 11.65 P/E ratio. The Company’s products include a commercial line of natural active ingredients, including beta glucan, avenanthramides , oat powder, oat oil, oat peptides and lupin peptides, which are marketed to the personal care, cosmetic, medical and animal health industries, and Veterinary therapeutic products, including an oat shampoo, an ear cleanser and a dermal complex/conditioner, which are manufactured and marketed to veterinarians in Japan and Asia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.